[New guideline for the treatment of osteoporosis].
Matsumoto
Toshio
T
Department of Medicine and Bioregulatory Sciences, University of Tokushima Graduate School of Medicine.
D019386:Alendronate / Q000627:therapeutic use*; D002116:Calcitonin / Q000627:therapeutic use*; D002118:Calcium / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D006801:Humans; D015201:Meta-Analysis as Topic; D010024:Osteoporosis / Q000188:drug therapy*; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D000068296:Risedronic Acid; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use*; D014807:Vitamin D / Q000627:therapeutic use*; D024482:Vitamin K 2 / Q000627:therapeutic use*
D020845:Selective Estrogen Receptor Modulators; D024482:Vitamin K 2; D014807:Vitamin D; D002116:Calcitonin; D000068296:Risedronic Acid; D012968:Etidronic Acid; D002118:Calcium; D019386:Alendronate